Bone Biologics Achieves 32-Month Validated Shelf Life for rhNELL-1

Bone Biologics (NASDAQ: BBLG) announced that the validated shelf life of its rhNELL-1 protein has been extended to 32 months, supported by third-party stability data.

Rhea-AI Summary

Bone Biologics (NASDAQ: BBLG) announced that the validated shelf life of its rhNELL-1 protein has been extended to 32 months, supported by third-party stability data. Management states this milestone enhances manufacturing flexibility, lot sizing, inventory management and distribution planning as the company prepares for pivotal-study scale.

The 32‑month validation builds on prior 12-, 18-, 24- and 29‑month shelf-life milestones achieved since 2025. Bone Biologics’ lead candidate NB1 combines rhNELL-1 with demineralized bone matrix and is being evaluated in a multicenter, randomized pilot study in up to 30 subjects with degenerative disc disease in Australia.

Positive

• rhNELL-1 shelf life validated at 32 months, up from prior 29-month milestone
• Third-party stability data support the extended rhNELL-1 shelf-life validation
• NB1 pilot study underway in up to 30 subjects with degenerative disc disease

Negative

• None.

Argus Aug 12 session 100 alerts

-28.61% close to close 12300.7x rel. volume Open Argus

Details

Market reaction after 32-month shelf-life milestone: BBLG -28.61% in the Aug 12 session

+55.2% Peak Tracked

-35.5% Trough Tracked

$2.61M Market Cap

In the Aug 12 session, BBLG declined 28.61%, reflecting a significant negative market reaction. Argus tracked a peak move of +55.2% during that session. Argus tracked a trough of -35.5% from its starting point during tracking. Our momentum scanner triggered 100 alerts that day, indicating very high trading interest and price volatility. Trading volume was exceptionally heavy at 12300.7x the daily average, suggesting significant selling pressure.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock dropped -28.6% in the session following this news. The -8.84% reaction to news_id 1079110 ...

Analysis

The stock dropped -28.6% in the session following this news. The -8.84% reaction to news_id 1079110 shows that recent corporate-development news was not uniformly supported by the market record. The new manufacturing milestone should be viewed separately from financing-related dilution and execution risks.

Key Figures

Validated shelf life: 32 months Prior shelf-life milestone: 29 months Earlier shelf-life milestone: 24 months +3 more

Validated shelf life

32 months

rhNELL-1 protein

Prior shelf-life milestone

29 months

Announced in May 2026

Earlier shelf-life milestone

24 months

Achieved in December 2025

Earlier validated shelf life

12 months

Earlier company milestone

Earlier validated shelf life

18 months

Earlier company milestone

Study size

Up to 30 subjects

Multicenter pilot study in Australia

Historical Context

3 past events · Latest: Jul 23

3 events

1. Jul 23

   Mid-year progress update

   24h Move

   -1.8%

   Financing, clinical progress, and 29-month shelf-life milestone preceded a negative reaction.

2. Jul 07

   Private placement

   24h Move

   -8.8%

   Private placement raised approximately $3.0 million upfront with additional warrant potential.

3. May 19

   Shelf-life milestone

   24h Move

   +0.8%

   Validated rhNELL-1 shelf life extended from 24 months to 29 months.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

first-in-human, pivotal-study, demineralized bone matrix, transforaminal lumbar interbody fusion

4 terms

first-in-human medical

"as our first-in-human NB1 study advances toward completion of enrollment."

A first-in-human study is the initial test of a new drug, medical device, or therapy in people to check safety, side effects and appropriate dosing. It matters to investors because it marks a major development milestone: successful early human testing can reduce scientific and regulatory uncertainty, much like moving a prototype from the workshop to a real-world test drive, and often affects a company’s valuation and funding prospects.

pivotal-study medical

"as we prepare for pivotal-study scale"

A pivotal study is a late-stage clinical trial whose results are intended to provide the main evidence that a medical product works and is safe enough for regulatory approval or market authorization. It matters to investors because its outcome often determines whether a product can be sold, like a final exam or tipping-point test that can unlock commercial revenue or halt a development program.

demineralized bone matrix medical

"combines rhNELL-1 protein with demineralized bone matrix"

Demineralized bone matrix is human bone that has had its mineral components removed, leaving a protein-based scaffold that helps the body grow new bone. Think of it as a biological framework or scaffold that surgeons use in orthopedics and dental procedures to support healing and tissue regrowth. For investors, it matters because its clinical utility, regulatory clearance, manufacturing quality, and adoption by surgeons affect product demand, company revenue, and reimbursement dynamics in the medical products market.

transforaminal lumbar interbody fusion medical

"undergoing transforaminal lumbar interbody fusion in Australia."

A transforaminal lumbar interbody fusion is a type of spine surgery that stabilizes two adjacent lower-back vertebrae by reaching the disc space through the natural side opening where spinal nerves exit, removing damaged disc material, and placing bone graft and an implant to fuse the bones together. Investors care because the procedure drives demand for spinal implants, surgical devices, hospital services, rehabilitation and insurance payments, so trends in its use, outcomes and reimbursement affect medical device makers, hospitals and payers much like sales trends affect any product line.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Milestone strengthens manufacturing flexibility and supports pivotal study readiness

BURLINGTON, Mass, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announces that the validated shelf life of its rhNELL-1 protein has been extended to 32 months.

“Reaching a 32-month validated shelf life gives us greater flexibility in how we manufacture, store and distribute rhNELL-1 as we prepare for pivotal-study scale,” said Jeff Frelick, Chief Executive Officer. “We have achieved each stability milestone on the timeline communicated to shareholders. By extending the period the product can be held before use, we believe this milestone supports more efficient lot sizing, inventory management and distribution planning as our first-in-human NB1 study advances toward completion of enrollment.”

The extension is supported by third-party stability data and builds on the 29-month milestone announced in May 2026 and the 24-month milestone achieved in December 2025, continuing a progression from the Company's earlier validated 12- and 18-month shelf-life milestones. A 32-month validated shelf life is expected to further enhance manufacturing efficiency, lot sizing, inventory management, distribution planning, and supply-chain flexibility as the Company advances rhNELL-1 through development.

NB1, the Company’s lead product candidate, combines rhNELL-1 protein with demineralized bone matrix to provide controlled bone regeneration. Bone Biologics is currently conducting a multicenter, prospective, randomized pilot clinical study evaluating NB1 in up to 30 subjects with degenerative disc disease undergoing transforaminal lumbar interbody fusion in Australia.

About Bone Biologics
Bone Biologics was founded to pursue regenerative medicine for bone. The Company is undertaking work with select strategic partners that builds on the preclinical research of the NELL-1 protein. Bone Biologics is focusing development efforts for its bone graft substitute product on bone regeneration in spinal fusion procedures, while additionally having rights to trauma and osteoporosis applications. For more information, please visit www.bonebiologics.com.

Forward-Looking Statements
Certain statements contained in this press release, including, without limitation, statements regarding the timing, implementation, and success of the Company's pilot clinical study, the Company’s development of rhNELL-1 and achievement of operational milestones, the ability of the Company’s lead product candidate NB1 to provide rapid, specific and guided control over bone regeneration and show fusion success in humans, the ability of NB1 to compete in global markets, as well as statements containing the words "may," "believe," "expect," and words of similar import, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company’s actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including, but not limited to, market and other conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under "Risk Factors" and "Management’s Discussion and Analysis of Financial Condition and Results of Operations" in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 and the Company’s other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof.

Contacts

CORE IR
(212) 655-0924
investors@bonebiologics.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Bone Biologics (NASDAQ: BBLG) announce about rhNELL-1 on August 12, 2026?

Bone Biologics announced that the validated shelf life of its rhNELL-1 protein has been extended to 32 months. According to Bone Biologics, this extension is supported by third-party stability data and is intended to improve manufacturing flexibility and supply-chain planning for future pivotal studies.

Why is a 32-month validated shelf life for rhNELL-1 important for Bone Biologics (BBLG) shareholders?

A 32-month validated shelf life may help Bone Biologics manufacture, store and distribute rhNELL-1 more efficiently. According to Bone Biologics, the longer shelf life can support lot sizing, inventory management and distribution planning as NB1 development advances, potentially improving operational execution for the program.

How does the new 32-month rhNELL-1 shelf-life compare to previous Bone Biologics milestones?

The 32-month validated shelf life extends a progression from earlier 12-, 18-, 24- and 29-month milestones. According to Bone Biologics, the latest validation builds specifically on the 29-month milestone announced in May 2026 and the 24-month milestone reported in December 2025.

What is Bone Biologics’ NB1 product candidate mentioned in the August 12, 2026 BBLG update?

NB1 is Bone Biologics’ lead product candidate that combines rhNELL-1 protein with demineralized bone matrix. According to Bone Biologics, NB1 is designed to provide controlled bone regeneration for spinal fusion procedures, particularly in patients with degenerative disc disease undergoing lumbar fusion surgery.

What clinical study is evaluating NB1 for Bone Biologics (NASDAQ: BBLG)?

Bone Biologics is conducting a multicenter, prospective, randomized pilot study of NB1 in Australia. According to Bone Biologics, the trial is evaluating NB1 in up to 30 subjects with degenerative disc disease undergoing transforaminal lumbar interbody fusion surgery.

How could the 32-month rhNELL-1 shelf life affect Bone Biologics’ pivotal-study readiness?

The 32-month shelf life is expected to support preparation for pivotal-study scale by improving manufacturing and logistics. According to Bone Biologics, extended stability can enhance lot sizing, inventory management, distribution planning and overall supply-chain flexibility as NB1 moves through clinical development.